Coverage
-
December 12, 2023
Novartis Pharmaceuticals has agreed to pay $182 million to Daiichi Sankyo subsidiary Plexxikon as part of a settlement in a patent infringement case over skin cancer drug Tafinlar after Novartis appealed a 2022 decision awarding Plexxikon $177.8 million, plus royalties.
12 other articles on this case.
View all »